期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (3)
Introduction Cardiovascular disease (CVD) is the leading cause of death in western countries. Although surgical outcomes for CVD are dramatically impr......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (1)
Introduction Recurrent pericarditis (RP) is a debilitating disease that has an underlying autoinflammatory pathophysiology mediated by cytokine interl......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (10)
Introduction There is growing interest in the development of multiple presentations for biological products for subcutaneous (SC) injection for life c......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (11)
Introduction The involvement of B-cells in multiple sclerosis has only recently emerged. Ublituximab is a monoclonal antibody that binds to the B-cell......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (12)
Background Real-world data for guselkumab, the first interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis, are scarce. This study r......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (12)
Background Real-world data on guselkumab, especially at times >6 months, are limited. Research design and methods We performed a longitudinal, retr......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (10)
Introduction Diabetic retinopathy (DR) is one of the most frequent microvascular complications of diabetes that can lead to blindness. Laser treatment......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (11)
Introduction Oncolytic adenoviruses (Ads) are promising therapeutics to enhance anti-tumor immune responses and modulate the immune-suppressive tumor ......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (11)
Introduction Newly approved immunotherapies for neuromyelitis optica spectrum disorder (NMOSD) have transformed the treatment landscape and improved d......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (2)
Objectives To review the real-life data, to provide an input to the literature concerning treatment of juvenile idiopathic arthritis (JIA) with adalim......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (2)
Background Bevacizumab, an inhibitor of angiogenesis, has been approved in several anti-cancer therapies. This study compared the pharmacokinetic (PK)......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (7)
Introduction: Melittin (MLT), a natural membrane-active component, is the most prominent cytolytic peptide from bee venom. Remarkable biological prope......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (11)
Introduction Esophageal cancer (EC) is the ninth most common cancer in Japanese men. Esophageal squamous cell carcinoma (ESCC) is the major histologic......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (11)
Introduction Over the last two decades, an increasing body of research suggests that well-designed biomaterials can attract resident stem cells to inj......
